Chief Scientific Officer (CSO)
Evolution Research Group
Clayton A. Dehn, M.S., Ph.D. (In Progress) is the Chief Scientific Officer and Executive Vice President – Scientific Services & Therapeutic Area Lead – Metabolism & Endocrinology at Evolution Research Group (ERG). With extensive experience in clinical pharmacology and drug development, he specializes in metabolism and endocrinology, particularly in obesity and metabolic disorders.
Mr. Dehn has led numerous clinical trials evaluating emerging metabolic therapies, with expertise spanning early-phase pharmacodynamic modeling, biomarker validation, and regulatory strategy. He chairs both the Obesity Drug Development Task Force and ERG’s Publication & Dissemination Group, initiatives aimed at advancing clinical research and scientific communication in the field. Additionally, he serves on the Metabolic Disorders Steering Committee of the Foundation for the National Institutes of Health (FNIH), contributing to collaborative research efforts focused on improving metabolic disease treatment and biomarker development.